Use of prescription medicines in Australian women of child-bearing age by Svetla Gadzhanova & Elizabeth Roughead
RESEARCH ARTICLE Open Access
Use of prescription medicines in Australian
women of child-bearing age
Svetla Gadzhanova* and Elizabeth Roughead
Abstract
Background: This study aimed to examine current utilisation of prescribed medicines amongst Australian women
of child-bearing age, with a particular focus on the extent of use of medicines in Category D and X risk groups,
which are moderate and high risk teratogens, respectively. The use of those medicines may pose risk of birth
defects in pregnant women.
Methods: A retrospective cross-sectional study was undertaken involving all women of child-bearing age (15 to 44 years)
who were dispensed medicines in 2013 using the 10 % random sample of dispensing data from the Australian
Government Department of Human Services. Dispensing patterns were reported by medicine, therapeutic class,
pregnancy risk category and women’s age.
Results: Over one-third of women aged 15 to 44 years received at least one prescribed medicine in 2013.
Psychoanaleptics, antibiotics and analgesics were the top three classes. Around 9 % of all dispensings were for
medicines from risk category D, with statins, agents acting on renin-angiotensin system, and some anti-epileptic
agents being the most commonly used. Both statins and agents acting on renin-angiotensin system showed
increasing use with age, estimated to be 35,600 women nationally for each group. Collectively between 2 % and
4 % of women used anti-epileptics from risk category D in each year of age, with overall use estimated to be
51,000 women nationally. Below 1 % of all dispensings were for category X medicines, mainly isotretinoin.
Conclusions: It is important for medical practitioners to offer counselling around pregnancy planning and the
risk of birth defects when prescribing moderate or high risk teratogens to women in child-bearing age. For the
antihypertensives and some anti-epileptics, alternative medicines with lower risk categorization are available.
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Background
Six percent of women of child-bearing age (15 to 44 years)
gave birth in Australia in 2012 [1]. Pregnancy creates chal-
lenges for peri-conception care as there is potential for
unintentional exposure to teratogenic substances, includ-
ing medicines. It is important for prescribers to be aware
of teratogenic drug-induced effects in women who are or
could become pregnant. Prescribers are likely to be aware
of the very few medicines that are considered “high-risk”
teratogens and should be absolutely avoided in pregnancy
(e.g. isotretinoin), which cause major birth deformities at
rates of 1 in 4 exposed foetuses [2]. The extent of use of
medicines that are considered lower or moderate risk of
harm in women of child-bearing age is less well studied.
The “moderate-risk teratogens” cause birth defects in a
smaller proportion of pregnancies but still have a 5 to
20 fold increase in specific risk [2] (e.g. carbamazepine
and sodium valproate) and in many cases safer alterna-
tives are available.
Category D medicines are those which may be consid-
ered moderate risk teratogens and are defined as medi-
cines which have caused, or are suspected to have caused
an increased incidence of human foetal malformations or
irreversible damage [3]. Some commonly prescribed medi-
cines, including statins and the antihypertensive medicines
acting on the renin-angiotensin system are category D
medicines. In the antidepressant class, paroxetine is consid-
ered category D, whilst amongst antiepileptics, topiramate,
lamotrigine, carbamazepine, sodium valproate, phenytoin
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and oxcarbazepine are all category D. For many of
these medicines, alternative agents are available and
should be considered where women are at risk of un-
planned pregnancies.
A systematic review of Australian studies using national
health data identified that use of medicines in pregnant
women is an area where more research is required [4].
The majority of prior Australian studies from Western
Australia (WA) linked pregnancy events in WA from 2002
to 2005 to national pharmaceutical claims (Pharmaceutical
Benefits Scheme (PBS) data). One of the studies reported
that in 28 % of all pregnancy events, women were exposed
to a PBS medicine while pregnant [5]. While studies have
examined medicine use in women during pregnancy, we
located no Australian studies that have examined medicine
utilisation for women of child-bearing age, particularly the
use of medicines that may be teratogenic.
Aim of the study
This study aimed to examine current utilisation of pre-
scribed medicines amongst Australian women of child-
bearing age, with a particular focus on the extent of use
of medicines in category D and X risk groups, which are
moderate and high risk teratogens, respectively.
Method
De-identified national pharmacy claims data from the
Australian Government Department of Human Services
were utilised, providing a 10 % random sample of people
who had medicines subsidised and dispensed under the
Pharmaceutical Benefits Scheme (PBS) [6]. Under the PBS,
the Australian Government subsidised the medicine cost
above the co-payment threshold. The co-payment is the
amount paid by the patients towards the cost of their PBS
medicines. From 1 January 2012, general patients pay up
to $35.40 for most PBS medicines or $5.80 if they have a
concession card. PBS data is collected from pharmacies
and public and private hospitals. It includes information
on patient age, gender, beneficiary status (general or con-
cessional beneficiary status), as well as dispensing informa-
tion, which includes date of supply, drug code, therapeutic
class, generic name, form, quantity dispensed and number
of repeats. Since 2012, PBS data represents full capture of
dispensing records for both general and concessional
beneficiaries. Medicines were coded in the dataset accord-
ing to the World Health Organization Anatomical Thera-
peutic Chemical (ATC) classification system [7].
A retrospective cross-sectional study was undertaken in-
volving all women of child-bearing age (15 to 44 years)
who were dispensed medicines in 2013. Both general and
concessional beneficiaries were included as data comprised
all subsidized medicines, including those below the co-
payment threshold. The pregnancy risk category for each
medicine was determined using the pregnancy database
provided by the Therapeutic Goods Administration,
Australian Government Department of Health [3]. There
are 7 categories under the Australian categorisation of the
risk of drug use in pregnancy (Table 1) [3]. Drugs from
category A are considered to be safe for use; drugs from
category B1, B2, B3 have not been shown to increase the
frequency of malformation or harmful effects on the hu-
man foetus; drugs from category C may cause harmful ef-
fects on the human foetus without causing malformations.
Drugs from categories D and X are considered moderate
to high risk medicines as they increase the incidence of
human foetal malformations and lead to irreversible and
Table 1 Definitions of the Australian categories for prescribing
medicines in pregnancy [3]
Category A
Drugs which have been taken by a large number of pregnant women
and women of childbearing age without any proven increase in the
frequency of malformations or other direct or indirect harmful effects
on the fetus having been observed.
Category B1
Drugs which have been taken by only a limited number of pregnant
women and women of childbearing age, without an increase in the
frequency of malformation or other direct or indirect harmful effects
on the human fetus having been observed.
Studies in animals have not shown evidence of an increased occurrence
of fetal damage.
Category B2
Drugs which have been taken by only a limited number of pregnant
women and women of childbearing age, without an increase in the
frequency of malformation or other direct or indirect harmful effects
on the human fetus having been observed.
Studies in animals are inadequate or may be lacking, but available data
show no evidence of an increased occurrence of fetal damage.
Category B3
Drugs which have been taken by only a limited number of pregnant
women and women of childbearing age, without an increase in the
frequency of malformation or other direct or indirect harmful effects
on the human fetus having been observed.
Studies in animals have shown evidence of an increased occurrence of
fetal damage, the significance of which is considered uncertain in
humans.
Category C
Drugs which, owing to their pharmacological effects, have caused or
may be suspected of causing, harmful effects on the human fetus or
neonate without causing malformations. These effects may be
reversible. Accompanying texts should be consulted for further details.
Category D
Drugs which have caused, are suspected to have caused or may be
expected to cause, an increased incidence of human fetal
malformations or irreversible damage. These drugs may also have
adverse pharmacological effects. Accompanying texts should be
consulted for further details.
Category X
Drugs which have such a high risk of causing permanent damage to
the fetus that they should not be used in pregnancy or when there is a
possibility of pregnancy.
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permanent damage. For combination products the cat-
egorisation was based on the component with the most
restrictive category. For this analysis, we excluded med-
icines where there were less than 400 dispensings per
year, which accounted for less than 0.03 % of all dis-
pensings for each medicine and represented 2.8 % of
total use.
We specifically examined medicines with potential
teratogenic effect. Analysis included the antidepres-
sants: paroxetine (category D), fluoxetine and sertraline
(both category C). A recent meta-analysis found parox-
etine and fluoxetine were associated with excess risk of
birth defects, but previously reported birth defects were
not confirmed for sertraline [8]. With regards to anti-
epileptics, topiramate, lamotrigine, carbamazepine, so-
dium valproate, phenytoin and oxcarbazepine are all
category D. Agents acting on renin-angiotensin system
are all category D, with alternative antihypertensives
available. Statins are also category D, however, limited
pharmacological alternatives are available, with non-
pharmacological therapies an alternative option for
some women.
Prescribing patterns were reported by medicine thera-
peutic class [7], pregnancy risk category [3] and patient
year of age. To extrapolate to national estimates of preva-
lence of use, we multiplied the results by a factor of ten,
because our sample was 10 %, and used the Australian
Bureau of Statistics population estimates of women age
15 to 44 years at 30 June 2013 [9]. Birth rates were also
presented based on number of births by mother’s age in
2013 [10]. The use of selected medicines was presented
as the rate of unique (distinct) women who received
that medicine in 2013 as a proportion of all unique
women in the given age group with at least one PBS
subsidised medicine in 2013. Student’s t-test was used
to compare means between any two groups.
Ethics
The study was approved by the Department of Human
Services (DHS) External Request Evaluation Committee
for analysis of PBS data. All analysis were conducted
using de-identified data and in accordance with DHS
Privacy Policy.
Results
There were 1,282,720 dispensings for 188,412 unique
women aged 15 to44 years in 2013 (mean age 30.3,
SD = 8.6). This approximates to 39 % of women of child-
bearing age nationally receiving at least one dispensed
medicine. Figure 1 presents the estimated birth rates and
rates of women dispensed at least one medicine by age
groups. One-third or more of the women in each age
group received at least one medicine in 2013, however
those with the highest birth rates (25 to 34 years) had
slightly lower medicine use.
We identified and categorized 265 medicines which
had 400 or more dispensings. Table 2 presents the pro-
portion of women and frequency of use of medicines by
pregnancy risk category. Medicines from categories A,
B3 and C were the most commonly dispensed, with
proportions ranging from 21 % (category A) to 27 %
(category C). 10 % of all dispensings were for medicines
from category D (9.3 %) or X (0.6 %) with women re-
ceiving category X medicines (predominantly isotreti-
noin) being younger.
The top 15 therapeutic classes dispensed to women
aged 15 to 44 years, contributed to 84 % of all dispensings
in the PBS sample (Fig. 2). One fifth of all dispensings
were for psychoanaleptics, followed by antibiotics (14 %),
analgesics (9 %) and psycholeptics (9 %). We examined
the medicines within each of those 15 therapeutic groups
by risk category and generic name (Fig. 2 and Table 3).
For the first group of psychoanaleptics, most dispensings
Fig. 1 Birth rate and rate of unique women dispensed at least one PBS subsidised medicine in 2013 as proportion of estimated female resident
population at 30 June 2013 (by age)
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were for antidepressants from C category, followed by
B2 category (Fig. 2). Table 3 lists the individual medi-
cines and shows that desvenlafaxine was most common,
followed by sertraline.
High and moderate risk teratogens - categories D
(contraindicated) and X (absolutely contraindicated)
Category D medicines contributed to 9.3 % of all dispens-
ings in 2013, while category X – to 0.6 %. There were
30,039 unique women (16 % of all 188,412 women) who
had medicine(s) from category D or X at some point of
time in 2013. Doxycycline was the most commonly used
drug from category D (by volume of dispensings), followed
by rosuvastatin, lamotrigine, sodium valproate, atorvastatin
and topiramate. Isotretinoin (anti-acne preparation for sys-
temic use) was the most commonly prescribed drug from
category X (84 % of all dispensings in this category),
followed by leflunomide (immunosuppressant).
The use of specific medicines that may pose increased
risk of birth defects are presented in Fig. 3. There was in-
creasing use of agents acting on renin-angiotensin system
and statins with age, both showing use below 1 % in women
under 30 years, 1 % to 4 % between 31 and 40 years, and
up to 7 % in those aged 44 years. This equates to an esti-
mated 35,600 women nationally for each of the two drug
groups. Paroxetine, a Category D medicine, was used by
1 % or less of women in each year of age – this equates to
1,100 women nationally aged 15 to 20; 3,800 women aged
21 to 30, and 8,200 women aged 31 to 44. Fluoxetine had
the highest rates of use in women below 20 years, and ser-
traline was used by 4 % or less of women in each year of
age. Rates of use of the anti-epileptics (category D) were
similar across all age groups and agents, with collective
use between 2 % and 4 % in each year of age. Their overall
use was estimated to be 51,000 women nationally, with
valproate being used by 22,700 women, topiramate by
11,100, lamotrigine by 9,000, and carbamazepine by 8,200
women. Use of isotretinoin (category X) and minocycline
Table 2 PBS medicines dispensed in women aged 15 to 44 in




(Total N = 1282720)
Unique women




A 270169 (21.1 %) 48.6 % 29.9
B1 95685 (7.5 %) 23.0 % 30.6
B2 110093 (8.6 %) 11.9 % 31.1
B3 298430 (23.3 %) 52.8 % 30.4
C 343917 (26.8 %) 28.9 % 32.0
D 118943 (9.3 %) 15.0 % 31.3
X 7901 (0.6 %) 1.2 % 24.9*
The percentages of dispenses sum up to 97.2 % as we categorized only
medicines with 400 or more dispensings in 2013
The percentages of unique women sum up to over 100 as many women had
medicines from multiple categories
*Significantly younger than women dispensed medicines from any one of the
remaining risk categories (student T-test, p < 0.0001)
Fig. 2 Top 15 therapeutic classes (by ATC category, level2), ordered by percentage of all dispensings in 2013; presented by pregnancy risk
category (visualize pregnancy category proportions > =2 % within a class)
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Table 3 Top 15 therapeutic classes (by ATC category, level2) by pregnancy risk category and generic name ordered by descending number of dispensings (ND)
Therapeutic group Category A Category B1 Category B2 Category B3 Category C Category D
Psycho-analeptics (NW : 42095)
(ND : 245976)
Reboxetine (0.6 %) Desvenlafaxine
(16.2 %)
Duloxetine (9.5 %) Sertraline (14.2 %) Paroxetine (3.1 %)
(N = 6574 dispenses)
Venlafaxine
(13.3 %)
Mirtazapine (6.4 %) Escitalopram (14.0 %)
Methylphenidate
(1.3 %)
Dexamphetamine (1.1 %) Fluoxetine (8.8 %)








Anti-bacterials for systemic use
(NW: 106522) (ND: 178481)
Amoxycillin (26.0 %) Amoxycillin with
Clavulanic acid
(17.0 %)








Flucloxacillin (3.6 %) Ciprofloxacin (0.3 %)
Erythromycin (4.2 %) Cefaclor (2.5 %) Norfloxacin (0.3 %)
Clindamycin (1.2 %) Azithromycin (1.9 %)






Rizatriptan (2.3 %) Sumatriptan (3.3 %) Oxycodone (17.5 %)
Paracetamol (11.1 %) Pizotifen (1.9 %) Zolmitriptan (0.4 %) Tramadol (13.5 %)









































Drugs for obstructive airway
diseases (NW: 34757)
(ND: 88275)
Salbutamol (30.9 %) Tiotropium (1.1 %) Fluticasone with
salmeterol (33.9 %)
Budesonide (2.1 %) Ipratropium (1.1 %) Budesonide with
eformoterol (26.0 %)
Terbutaline (1.4 %) Nedocromil (1.1 %) Fluticasone (4.2 %)
Ciclesonide (1.0 %)
Sex hormones and modulators
of the genital system










Etonogestrel (19.3 %)a Medroxyprogesterone



























Ranitidine (7.2 %) Pantoprazole (16.4 %)
Esomeprazole and amoxicilan






Gabapentin (1.9 %) Pregabalin (29.0 %) Clonazepam (1.9 %) Valproate (29.1 %)
(N = 8364)
Levetiracetam (7.8 %) Topiramate (14.3 %)
(N = 7607)
Lacosamide (1.0 %) Lamotrigine (11.6 %)
(N = 8803
Carbamazepine






(NW: 14676) (ND: 25747)
















Drugs used in diabetes
(NW: 6792) (ND: 21668)
Insulin aspart (23.8 %) Insulin glargine (16.0 %) Metformin (40.4 %)
Insulin (human) (8.7 %) Sitagliptin (1.8 %) Gliclazide (5.5 %)
Insulin lispro (5.7 %) Metformin with
sitagliptin (3.0 %)






















(NW: 3842) (ND: 20916)
Fenofibrate (5.6 %) Rosuvastatin (45.3 %)
(N = 9225)



































(4.2 %) (N = 722)
Candesartan with HCTZ
















Table 3 Top 15 therapeutic classes (by ATC category, level2) by pregnancy risk category and generic name ordered by descending number of dispensings (ND) (Continued)
Antivirals for systemic use
(NW: 6837) (ND: 16556)









The % reported for each medicine is from the number of unique women (NW) receiving the given therapeutic group. If the percentages of unique women sum up to over 100 it denotes that some women received
multiple medicines from the same therapeutic class in 2013. For medicines in pregnancy risk category D we also reported the number of dispenses
















(category D) were highest in younger women, used by an
estimated 20,700 women nationally for isotretinoin and
13,600 women for minocycline.
Discussion
We found that over one-third of the women aged 15 to
44 years in Australia had received at least one medicine
in 2013. Those aged 25 to 34 years had the highest birth
rates and slightly lower medicine use.
We found that the majority of use was for medicines
considered relatively safe in pregnancy (categorised in A
or B risk groups). Our results have some similarities to
previous Australian research assessing medicine use in
pregnant women. The rates for psychoanaleptics, antibi-
otics, analgesics and psycholeptics that we found among
women of child-bearing age were similar to that found
previously in pregnant women [5]. In both studies simi-
lar proportions were for Category C medicines (27 % in
our study compared with 26 % as reported by [5]).
Higher rates of Category A medicines were found among
pregnant women (43 %) [5] compared to 21 % in our
study. The use of iron with folic acid (anti-anemic
preparation) and metoclopramide (for nausea and vomit-
ing) in pregnancy are likely to account for this difference.
Category D medicines contributed to 9 % of all dispens-
ings in our study compared to 5 % of all dispensings in
pregnant women [5]. Both studies found very low use of
category X medicines (below 1 %). The relatively low use
of category D and X medicines in pregnant women and in
all women of child-bearing age implies caution when pre-
scribing those moderate or high risk teratogens to women.
Women of child-bearing age may have chronic condi-
tion (e.g. hypertension or epilepsy) which require medi-
cine(s) therapy. Hypertensive disorders are common and
management of chronic hypertension is essential. As
some commonly prescribed antihypertensive drugs such
as agents acting on on renin-angiotensin system are cat-
egory D, they should be avoided before conception and
during pregnancy [11]. Pre-pregnancy counselling is es-
sential and drug treatment should be reserved for per-
sistent or severe hypertension with careful monitoring
due to the increased risk of adverse pregnancy outcomes
[11]. We found that up to 1 % of women under 30 years
of age, 1 % to 4 % between 31 and 40 years, and up to
Fig. 3 Use of selected medicines from category C, D and X which may pose increased risk of birth defects (by age). Legend: ^ Category C;
* Category D; ** Category X; ACE inhibitors – Angiotensin converting enzyme inhibitors; ARBs – angiotensin II receptor antagonists. SSRIs – Selective
serotonin reuptake inhibitors
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7 % of those aged 44 years were using agents acting on
the renin-angiotensin system from risk category D. For
pregnant women, antihypertensives with lower risk cat-
egory might be considered.
Antiepileptic medicines such as valproate [12–14] and
carbamazepine [12, 14–16] are associated with an in-
creased risk for major congenital malformations, including
neural tube defects and should be prescribed with caution
in pregnancy [17]. Topiramate is associated with an in-
creased risk for oral clefts [18, 19] and the Food and Drug
Administration (FDA) in US issued a change in label to
warn of the potential risk [20]. Lamotrigine might be asso-
ciated with an increase in the absolute risk for oral clefts
[18]. Collectively between 2 % and 4 % of women used
anti-epileptics from risk category D in each year of age.
Without data on indication, we cannot assess whether
there were alternative options. Loss of seizure control dur-
ing pregnancy is also a risk, and this level of use may
represent a consideration of risks and benefits.
The risk of congenital malformations associated with
maternal use of antidepressants, especially selective sero-
tonin reuptake inhibitors (SSRIs) as a group, appears to
be small and mostly non-significant [21–23], however,
meta analyses have found an association between spe-
cific SSRIs and birth defects. An increased risk for some
heart defects was observed with paroxetine use (Cat-
egory D) [8, 24, 25] as well as fluoxetine [8] (currently
Category C), while the evidence for sertraline (Category
C) is conflicting [8, 22, 23]. Overall, sertraline was the
most commonly dispensed of these three antidepres-
sants. Fluoxetine had the highest rates of use in women
below 20 years, and paroxetine was used by 1 % or less
of women in each year of age, despite the availability of
antidepressants with less risk potential.
We analyzed data from a national dataset capturing pre-
scription data of all Australians. We included both general
and concessional beneficiaries as since 2012 all below co-
payment prescriptions are recorded in the PBS data,
allowing for generalization of the results to the entire
Australian population. Our study was not intended to as-
sess medicine use in pregnancy. Our results are descrip-
tive only addressing national use of prescribed medicines
in Australian women of child-bearing age with special
focus on medicines that may be teratogenic. We could not
capture medicines that are not listed under the PBS and
are available over the counter or as private prescriptions.
Conclusion
It is important for medical practitioners to offer counsel-
ling around pregnancy planning and the risk of birth de-
fects when prescribing moderate or high risk teratogens
to women of child-bearing age. For the antihypertensives
and some anti-epileptics, alternative medicines with
lower risk categorization are available.
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